Chronic kidney disease (CKD) is a long-term condition in which kidney function declines over time, reducing the kidneys’ ability to filter blood and maintain fluid and electrolyte balance.
New noninvasive biomarkers are advancing early detection of fibrosis. A FAP-Index blood test reduces uncertain liver fibrosis results by up to 70%, a urine-based molecular imaging test detects kidney fibrosis with 84% sensitivity and 94% specificity, and liver MRE can track Gaucher disease severity over time.
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
In 2025, China's NMPA approved 289 new drug applications, including traditional Chinese medicines. A study reveals critical methodological gaps in clinical trials of herbal therapies, while a review highlights the potential of nanoformulations for renal fibrosis.
The FDA has approved Agios Pharmaceuticals' mitapivat (AQVESME) as the first oral treatment for anemia in thalassemia, reducing transfusion needs by 40-50%. Meanwhile, a clinical trial found a three-times-weekly dosing of vadadustat (Vafseo) is safe for kidney dialysis patients, potentially improving convenience.
Semaglutide improves kidney, survival, and quality-of-life outcomes in type 2 diabetes with CKD, per FLOW trial analyses. Benefits were consistent across cardiovascular and severity subgroups, adding eight full-health days per year.
NHMRC Tracker newsletters cover the new Research Translation Strategy 2026–2030, a revised generative AI policy, RRR Capacity Building grants, and consultations on drinking water and clinical guidelines.
A single-center study of 95 chronic kidney disease patients on hemodialysis found the Cy-TB skin test agreed completely with standard IGRA testing for latent tuberculosis, with an overall prevalence of 4.2%. Early dialysis phase (<6 months) was a strong predictor of positivity, suggesting a potential priority screening window, though larger confirmatory studies are needed.
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Unicycive Therapeutics received an FDA Complete Response Letter for its oxylanthanum carbonate NDA resubmission due to third-party manufacturing deficiencies. The FDA raised no efficacy or safety concerns and requested no new data. Labeling discussions are ongoing.
Trial: VPM1002/Immuvac show limited overall TB protection but up to 50.4% efficacy vs extrapulmonary TB. Modeling: blocking asymptomatic TB key to long-term vaccine impact. Also: STEP-TB safety study and CDC Asia funding.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07768865 |
Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney Disease |
RECRUITING | |
| NCT07765134 |
Comprehensive Kidney Function Assessment and Early Warning in Older Adults |
COMPLETED | |
| NCT07759401 |
Food As Medicine to Reduce CKD Burden in Health Disparity Populations |
NOT_YET_RECRUITING | NA |
| NCT07754097 |
Self-Management Data and Disease Progression in Chronic Kidney Disease |
RECRUITING | |
| NCT07753993 |
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07751939 |
Artificial Intelligence Model to Predict Chronic Kidney Outcomes in a Vietnamese Cohort |
ACTIVE_NOT_RECRUITING | |
| NCT07747363 |
Community-Based Screening for Chronic Kidney Disease |
COMPLETED | NA |
| NCT07746102 |
Assessment of the Impact of Repeated Ischemic Preconditioning Episodes on Hemodynamic and Metabolic Parameters in Patients at Various Stages of Chronic Kidney Disease |
RECRUITING | NA |
| NCT07741292 |
Niaoduqing Granules in Older Adults With Impaired Kidney Function |
RECRUITING | PHASE4 |
| NCT07741136 |
Pharmacokinetics of Zoledronic Acid in Patients on Dialysis |
NOT_YET_RECRUITING | PHASE1 |
